Eugene K Roberts

US Patent:

48310336, May 16, 1989

Filed:

Sep 9, 1988

Appl. No.:

7/243087

Inventors:

Eugene Roberts - Monrovia CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 31425
A61K 31495

US Classification:

514255

Abstract:

A procedure for the treatment of degenerative diseases of the central nervous system, including Alzheimer's disease, multiple sclerosis and the like, by the administration of amodiaquin and related compounds is disclosed.

US Patent:

63200244, Nov 20, 2001

Filed:

Mar 9, 1999

Appl. No.:

9/264709

Inventors:

Eugene Roberts - Monrovia CA

International Classification:

C07K 500
C07K 510
C07K 750

US Classification:

530330

Abstract:

A topographic model useful to design and synthesize memory-enhancing substances is disclosed. Administration of substances designed by this method to enhance memory in mammals, including humans, is disclosed. Such substances include peptides having the amino acid sequence Val Phe Phe.

US Patent:

54709512, Nov 28, 1995

Filed:

Sep 29, 1993

Appl. No.:

8/127904

Inventors:

Eugene Roberts - Monrovia CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3800
C07K 500
C07K 700
C07K 1700

US Classification:

530330

Abstract:

Three non-amnestic and non-memory enhancing peptides, Asp Phe Phe Val Gly (SEQ ID NO: 1), Gln Phe Val Gly (SEQ ID NO: 2), and Ala Ile Phe Thr (SEQ ID NO: 3), that block the effects of. beta. -(12-28), a peptide homologous to amyloid. beta. protein (A. beta. ) are disclosed. This invention relates to amelioration of amnesia and other neurotoxicitiy in Alzheimer disease (AD) caused by deposition of A. beta. and, therefore, relates to attenuation of the disease process and consequential improvement of the quality of life for individuals suffering from AD.

US Patent:

55740227, Nov 12, 1996

Filed:

Apr 14, 1994

Appl. No.:

8/227533

Inventors:

Eugene Roberts - Monrovia CA
Lloyd Guth - Ford's Colony VA

Assignee:

The Center for Innovative Technology - Herndon VA
The College of William and Mary - Williamsburg VA
City of Hope - Duarte CA

International Classification:

A61K 31715
A61K 3160
A61K 3156

US Classification:

514 54

Abstract:

A method is disclosed for attenuation of nervous system damage after injury which comprises administering therapeutic amounts of PREG, PREG-S, or esters of PREG or PREG-S together with an enhancer of secretory processes in non-neural cells such as a bacterial lipopolysaccharide and a non-steroidal antiinflammatory substance such as indomethacin.

US Patent:

48065374, Feb 21, 1989

Filed:

Mar 21, 1988

Appl. No.:

7/171371

Inventors:

Eugene Roberts - Monrovia CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3150
A61K 31495

US Classification:

514253

Abstract:

A procedure for the treatment of degenerative diseases of the central nervous system, including Alzeheimer's disease, multiple sclerosis and the like, by the administration of amodiaquin and related compounds is disclosed.

US Patent:

48681610, Sep 19, 1989

Filed:

Sep 14, 1987

Appl. No.:

7/097302

Inventors:

Eugene Roberts - Monrovia CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3170
A61K 31505
A61K 3117
A61K 3340

US Classification:

514 49

Abstract:

A method for promoting regeneration of damaged nerve tissue, comprising administering, either alone or in combination, an effective amount of an antimitotic agent or a proton-withdrawing buffer to the damage site. Antimitotic agents reduce the rate of growth of glial cells, and buffers facilitate the growth of nerve tissue and inhibit glial cell growth. Referred antimitotic agents are cytosine arabinoside, 5-fluorouracil, and hydroxyurea. Preferred buffers are TREA and HEPES. Compositions are disclosed which include antimitotic agent, buffer, and an oxygen-supplying compound, such as hydrogen peroxide.

US Patent:

48124478, Mar 14, 1989

Filed:

Dec 11, 1986

Appl. No.:

6/940789

Inventors:

Eugene Roberts - Monrovia CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3155
A61K 3156

US Classification:

514170

Abstract:

Disclosed is a method for treating nervous system deterioration associated with aging and Alzheimer's disease by administering a therapeutically-effective amount of dehydroepiandrosterone or its sulfate. Also disclosed is the co-administration of dehydroepiandrosterone or its sulfate and a potassium channel antagonist. The disclosure is also directed to pharmaceutical compositions containing dehydroepiandrosterone, alone or in combination with a potassium channel antagonist. Dehydroepiandrosterone is also shown to facilitate the growth of nervous system tissue, particularly in culture.

US Patent:

56523343, Jul 29, 1997

Filed:

Sep 8, 1993

Appl. No.:

8/117927

Inventors:

Eugene Roberts - Monrovia CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3800
C07K 510

US Classification:

530330

Abstract:

Amnestic novel peptides are disclosed. A topographical map or surface which includes binding sites for peptides having amnestic procedures and the use of such surface to identify and synthesize such peptides is also disclosed.

Address:

16815 Rolling Acres Dr, Humble, TX 77396

VIN:

1N4BA41E07C843945

Make:

NISSAN

Model:

MAXIMA

Year:

2007